477 related articles for article (PubMed ID: 26175415)
1. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
[TBL] [Abstract][Full Text] [Related]
2. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
Stewart CA; Byers LA
Cancer Cell; 2015 Jul; 28(1):4-6. PubMed ID: 26175409
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of LSD1 inhibitors in lung cancer.
Mohammad HP; Kruger RG
Mol Cell Oncol; 2016 Mar; 3(2):e1117700. PubMed ID: 27308632
[TBL] [Abstract][Full Text] [Related]
4. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
5. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
7. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
8. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
[TBL] [Abstract][Full Text] [Related]
9. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
10. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
[TBL] [Abstract][Full Text] [Related]
12. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
15. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Fang Y; Liao G; Yu B
J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
[TBL] [Abstract][Full Text] [Related]
16. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
17. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Christensen CL; Kwiatkowski N; Abraham BJ; Carretero J; Al-Shahrour F; Zhang T; Chipumuro E; Herter-Sprie GS; Akbay EA; Altabef A; Zhang J; Shimamura T; Capelletti M; Reibel JB; Cavanaugh JD; Gao P; Liu Y; Michaelsen SR; Poulsen HS; Aref AR; Barbie DA; Bradner JE; George RE; Gray NS; Young RA; Wong KK
Cancer Cell; 2014 Dec; 26(6):909-922. PubMed ID: 25490451
[TBL] [Abstract][Full Text] [Related]
18. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
19. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
[TBL] [Abstract][Full Text] [Related]
20. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
